Here, we emphasize the combinatory treatment of Talazoparib (PARP inhibitor) and Palbociclib (CDK4/6 inhibitor) as a potent therapy approach for BLCA. The gene discussed is CDK4; the disease is bladder transitional cell carcinoma.